Back to Search Start Over

Plasma steroid concentrations reflect acute disease severity and normalise during recovery in people hospitalised with COVID-19.

Authors :
Devine K
Russell CD
Blanco GR
Walker BR
Homer NZM
Denham SG
Simpson JP
Leavy OC
Elneima O
McAuley HJC
Shikotra A
Singapuri A
Sereno M
Saunders RM
Harris VC
Houchen-Wolloff L
Greening NJ
Lone NI
Thorpe M
Greenhalf W
Chalmers JD
Ho LP
Horsley A
Marks M
Raman B
Moore SC
Dunning J
Semple MG
Andrew R
Wain LV
Evans RA
Brightling CE
Kenneth Baillie J
Reynolds RM
Source :
Clinical endocrinology [Clin Endocrinol (Oxf)] 2024 Apr; Vol. 100 (4), pp. 317-327. Date of Electronic Publication: 2024 Jan 17.
Publication Year :
2024

Abstract

Objective: Endocrine systems are disrupted in acute illness, and symptoms reported following coronavirus disease 2019 (COVID-19) are similar to those found with clinical hormone deficiencies. We hypothesised that people with severe acute COVID-19 and with post-COVID symptoms have glucocorticoid and sex hormone deficiencies.<br />Design/patients: Samples were obtained for analysis from two UK multicentre cohorts during hospitalisation with COVID-19 (International Severe Acute Respiratory Infection Consortium/World Health Organisation [WHO] Clinical Characterization Protocol for Severe Emerging Infections in the UK study), and at follow-up 5 months after hospitalisation (Post-hospitalisation COVID-19 study).<br />Measurements: Plasma steroids were quantified by liquid chromatography-mass spectrometry. Steroid concentrations were compared against disease severity (WHO ordinal scale) and validated symptom scores. Data are presented as geometric mean (SD).<br />Results: In the acute cohort (n = 239, 66.5% male), plasma cortisol concentration increased with disease severity (cortisol 753.3 [1.6] vs. 429.2 [1.7] nmol/L in fatal vs. least severe, p < .001). In males, testosterone concentrations decreased with severity (testosterone 1.2 [2.2] vs. 6.9 [1.9] nmol/L in fatal vs. least severe, p < .001). In the follow-up cohort (n = 198, 62.1% male, 68.9% ongoing symptoms, 165 [121-192] days postdischarge), plasma cortisol concentrations (275.6 [1.5] nmol/L) did not differ with in-hospital severity, perception of recovery, or patient-reported symptoms. Male testosterone concentrations (12.6 [1.5] nmol/L) were not related to in-hospital severity, perception of recovery or symptom scores.<br />Conclusions: Circulating glucocorticoids in patients hospitalised with COVID-19 reflect acute illness, with a marked rise in cortisol and fall in male testosterone. These findings are not observed 5 months from discharge. The lack of association between hormone concentrations and common post-COVID symptoms suggests steroid insufficiency does not play a causal role in this condition.<br /> (© 2024 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd.)

Details

Language :
English
ISSN :
1365-2265
Volume :
100
Issue :
4
Database :
MEDLINE
Journal :
Clinical endocrinology
Publication Type :
Academic Journal
Accession number :
38229583
Full Text :
https://doi.org/10.1111/cen.15012